Tyrosine Kinase
- IGFBR(1)
- Bcr-Abl(73)
- Ack1(4)
- Axl(6)
- ALK(61)
- BMX Kinase(4)
- Broad Spectrum Protein Kinase Inhibitor(11)
- c-FMS(35)
- c-Kit(65)
- c-MET(91)
- c-RET(7)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(251)
- EphB4(2)
- FAK(34)
- FGFR(104)
- FLT3(102)
- HER2(19)
- IGF1R(33)
- Insulin Receptor(45)
- IRAK(32)
- ITK(12)
- Lck(2)
- LRRK2(23)
- PDGFR(117)
- PTKs/RTKs(5)
- Pyk2(6)
- ROR(41)
- Spleen Tyrosine Kinase (Syk)(35)
- Src(105)
- Tie-2 (3)
- Trk(37)
- VEGFR(203)
- Kinase(0)
- Discoidin Domain Receptor(15)
- DYRK(26)
- Ephrin Receptor(13)
- ROS(15)
- RET(34)
- TAM Receptor(28)
Products for Tyrosine Kinase
- Cat.No. Product Name Information
- GC17637 CTX0294885 Pan-kinase inhibitor
- GC16008 CUDC-101 A multi-target inhibitor of HDACs, EGFR, and HER2
- GC38180 Cyasterone
- GC13780 Cyclotraxin B TrkB receptor antagonist
- GC16731 CZC 54252 hydrochloride CZC 54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively.
- GC16038 CZC-25146 LRRK2 inhibitor
- GC35792 CZC-25146 hydrochloride CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively.
- GC33351 CZC-8004 (CZC-00008004) CZC-8004 (CZC-00008004) (CZC-00008004), an aminopyrimidine, is a pan-kinase inhibitor. CZC-8004 (CZC-00008004) can bind a range of tyrosine kinases, including EGFR and VEGFR2 with IC50 values of 650 and 437 nM, respectively.
- GC43433 D-Glucosamine-6-sulfate D-Glucosamine-6-sulfate is a naturally occurring glycosaminoglycan.
- GC62712 DA-JC4 DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
- GC10225 Dacomitinib (PF299804, PF299) Dacomitinib (PF299804, PF299) (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
- GC15211 Damnacanthal p56lck tyrosine kinase inhibitor
- GC15217 Danusertib (PHA-739358) A pan-Aurora kinase and Abl inhibitor
- GN10336 Daphnetin
- GC15568 Dasatinib (BMS-354825) An inhibitor of Abl and Src
- GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor
- GC15884 Dasatinib Monohydrate Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases.
- GC45687 Dasatinib N-oxide A major metabolite of dasatinib
- GC62569 DBPR112 DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.
- GC14007 DCC-2036 (Rebastinib) DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
- GC11171 DCC-2618 A dual inhibitor of c-Kit and c-MET
- GC33361 DDR Inhibitor DDR Inhibitor is a potent discoidin domain receptor (DDR) inhibitor, with an IC50 of 3.3 nM for DDR2, and shows 53% inhibition on DDR1 at 1.5 nM.
- GC17365 DDR1-IN-1 selective DDR1 receptor tyrosine kinase inhibitor
- GC35822 DDR1-IN-1 dihydrochloride DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC50 of 105 nM; 4-fold less potent for DDR2 (IC50 = 413 nM).
- GC31724 DDR1-IN-2 DDR1-IN-2 (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1), with an IC50 of 13.1 nM, and also less potently inhibits DDR2, with an IC50 of 203 nM.
- GC33297 DDR1-IN-3 DDR1-IN-3 is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC50 value of 9.4 nM. DDR1-IN-3 also inhibits TRK family.
- GC64268 DDR1-IN-4 DDR1-IN-4 (Compound 2.45) is a selective and potent Discoidin Domain Receptor 1 (DDR1) autophosphorylation inhibitor, with IC50 values of 29 nM and 1.9 μM for DDR1 and DDR2, respectively.
- GC65378 DDR1-IN-5 DDR1-IN-5 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 7.36 nM. DDR1-IN-5 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 4.1 nM. DDR1-IN-5 has anti-cancer activity.
- GC66476 DDR1-IN-6 DDR1-IN-6 is a selective Discoidin Domain Receptor family, member 1 (DDR1) inhibitor with an IC50 of 9.72 nM. DDR1-IN-6 inhibits auto-phosphorylation DDR1b (Y513) with an IC50 of 9.7 nM. DDR1-IN-6 has anti-cancer activity.
-
GC16813
Defactinib
FAK phosphorylation inhibitor
- GC35827 Defactinib hydrochloride A novel FAK inhibitor
- GC47182 Dehydrolithocholic Acid Dehydrolithocholic Acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (Kd=1.13 μM).
-
GC14905
Demethylasterriquinone B1
An insulin receptor (IR) activator
- GC19399 Derazantinib Derazantinib (ARQ-087) is an ATP competitive tyrosine kinase inhibitor; exhibits potent activity against FGFR1-3 chondrocytes with IC50s of 4.5, 1.8, and 4.5 nM, respectively.
- GC62107 DGY-06-116 DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM.
-
GC30768
Dihexa (PNB-0408)
Dihexa (PNB-0408) (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an oral active, blood-brain barrier-permeable angiotensin IV analogue.
- GC64039 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
- GC14298 DMH-1 Selective BMP ALK2 receptor
- GC17098 DMH4 VEGFR-2 inhibitor
- GC43503 DMHAPC-Chol DMHAPC-Chol is a cationic cholesterol.
- GC17024 DMPQ dihydrochloride PDGFRβ inhibitor
- GC10165 Dovitinib (TKI258) Lactate Dovitinib (TKI258) Lactate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
- GC11372 Dovitinib Dilactic acid FLT3 inhibitor
- GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
- GC45767 Dovitinib-d8 An internal standard for the quantification of dovitinib
- GC35897 DPH A potent cell permeable c-Abl activator
- GC62597 DS-1205b free base DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo.
- GC62946 DYRK1-IN-1 DYRK1-IN-1 is a highly selective and ligand-efficient DYRK1A inhibitor.
- GC62947 DYRKs-IN-1 hydrochloride DYRKs-IN-1 hydrochloride is a potent DYRKs (Dual-specificity tyrosine-phosphorylation-regulated kinases) inhibitor with IC50s of 5 nM and 8 nM for DYRK1A and DYRK1B, respectively. DYRKs-IN-1 hydrochloride has antitumor activity.
- GC12149 E-3810
- GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.
- GC66432 EAI001 EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC50 value of 24 nM for EGFRL858R/T790M. EAI001 can be used for research of cancer.
- GC12281 EAI045 Inhibitor of L858R/T790M EGFR mutants
- GC64730 EB-42486 EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM).
- GC32825 eCF506 An inhibitor of Src kinases
- GC67879 Edecesertib
- GC19418 Edicotinib Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease.
-
GC16183
EG00229
Nrp1 inhibitor
- GC16321 EGF816 EGF816 (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min-1 on EGFR(L858R/790M) mutant, respectively.
- GC11312 EGFR Inhibitor EGFR Inhibitor is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective EGFR inhibitor with an IC50of 21 nM. EGFR Inhibitor also inhibits mutant EGFRL858R and EGFRL861Q with IC50s of 63 nM and 4 nM, respectively. EGFR Inhibitor displays strong selectivity for EGFR over HER4 (IC50 = 7640 nM) and a panel of 55 other kinases. EGFR Inhibitor induces cells apoptosis and has antitumor activity.
- GC35965 EGFR mutant-IN-1 EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFRL858R/T790M/C797S mutant inhibitor with an IC50 of 27.5 nM, while being a significantly less potent for EGFRWT (IC50 >1.0 μM).
- GC65572 EGFR Protein Tyrosine Kinase Substrate EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.
- GC62562 EGFR-IN-11 EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC50 of 18 nM for triple mutant EGFRL858R/T790M/C797S. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.
- GC64497 EGFR-IN-17 EGFR-IN-17 is a potent and selective inhibitor of the epidermal growth factor receptor ( IC50 0.0002 μM) to overcome C797S-mediated resistance.
- GC33195 EGFR-IN-2 EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor.
- GC19132 EGFR-IN-3 EGFR-IN-3 is a third-generation EGFR TKI, with GI50 values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. EGFR-IN-3 has the potential for NSCLC research.
- GC66428 EGFR-IN-5 EGFR-IN-5 is a EGFR inhibitor with IC50s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively.
- GC68440 EGFR-IN-69
- GC35966 EGFR-IN-7 EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC50 values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 shows anti-tumor activity. EGFR-IN-7 can be used for the research of various cancers.
- GC65974 EGFR-IN-9 EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.
- GC14856 EGFR/ErbB2 Inhibitor EGFR/ErbB2 Inhibitor (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM.
- GC25367 Ehp-inhibitor-1 Ehp-inhibitor-1 (Ehp inhibitor 2) is an Eph family tyrosine kinase inhibitor that targets Eph receptors.
- GC38330 EHT 5372
-
GC10466
EMD-1214063
EMD-1214063 (Tepotinib, MSC2156119J) is a novel potent and highly selective reversible, ATP-competitive small molecule c-Met inhibitor .
- GC60805 EMI48 EMI48, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI48 inhibits EGFR triple mutants.
- GC62420 EMI56 EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants.
- GC65354 Enbezotinib Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer.
- GC16519 ENMD-2076 A multi-kinase inhibitor
- GC12145 ENMD-2076 L-(+)-Tartaric acid
- GC33190 Ensartinib (X-396) Ensartinib (X-396) (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
- GC32864 Ensartinib hydrochloride (X-396 hydrochloride) Ensartinib hydrochloride (X-396 hydrochloride) (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.
- GC38776 Ensulizole Ensulizole is a sulfonated UV absorber and can intense UVB and partial UVA absorption.
- GC14476 Entrectinib Orally active inhibitor of ALK kinase
- GC65380 Envonalkib Envonalkib is a potent and orally active inhibitor of ALK, with IC50s of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK. Envonalkib can be used for the research of non-small cell lung cancer.
- GC33048 Epertinib (S-22611) Epertinib (S-22611) (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib (S-22611) shows potent antitumor activity.
- GC38350 Epertinib hydrochloride Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.
- GC62384 Epitinib succinate Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer.
- GC63390 EPQpYEEIPIYL EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains.
- GC12958 ER 27319 maleate Selective inhibitor of Syk kinase
- GC52516 Erbstatin A tyrosine kinase inhibitor
- GC19142 Erdafitinib A pan-FGFR tyrosine kinase inhibitor
- GC10627 Erlotinib An EGFR tyrosine kinase inhibitor
- GC60154 Erlotinib D6 Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR.
- GC15600 Erlotinib Hydrochloride An EGFR tyrosine kinase inhibitor
- GC36003 Erlotinib mesylate EGFR inhibitor
- GC62958 Erlotinib-13C6 Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR.
- GC47303 Erlotinib-d6 (hydrochloride) An internal standard for the quantification of erlotinib
- GC36021 F-1 F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively.
- GC12174 FAK Inhibitor 14 FAK Inhibitor 14 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.
- GC36025 FAK inhibitor 2 FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor with an IC50 ?of 0.07?nM, with antitumor and anti-angiogenesis activities.